Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $31.7 million.

  • BridgeBio Pharma's Share-based Compensation rose 1667.83% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.6 million, marking a year-over-year increase of 2794.31%. This contributed to the annual value of $113.9 million for FY2024, which is 99.99% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Share-based Compensation stood at $31.7 million, which was up 1667.83% from $37.3 million recorded in Q2 2025.
  • BridgeBio Pharma's Share-based Compensation's 5-year high stood at $48.2 million during Q4 2024, with a 5-year trough of $16.1 million in Q3 2021.
  • Its 5-year average for Share-based Compensation is $28.3 million, with a median of $27.2 million in 2023.
  • Per our database at Business Quant, BridgeBio Pharma's Share-based Compensation skyrocketed by 24138.13% in 2021 and then tumbled by 3041.9% in 2022.
  • BridgeBio Pharma's Share-based Compensation (Quarter) stood at $22.5 million in 2021, then grew by 0.32% to $22.6 million in 2022, then surged by 64.42% to $37.1 million in 2023, then rose by 29.78% to $48.2 million in 2024, then plummeted by 34.31% to $31.7 million in 2025.
  • Its last three reported values are $31.7 million in Q3 2025, $37.3 million for Q2 2025, and $29.4 million during Q1 2025.